Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

Peer Review reports

Original Submission
6 Jun 2018	Submitted	Original manuscript
9 Jul 2018	Author responded	Author comments - Wei Xue
Resubmission - Version 2
9 Jul 2018	Submitted	Manuscript version 2
18 Oct 2018	Author responded	Author comments - Liancheng Fan
Resubmission - Version 3
18 Oct 2018	Submitted	Manuscript version 3
Publishing
26 Oct 2018	Editorially accepted
3 Dec 2018	Article published	10.1186/s12894-018-0416-6

Back to article page